WINT WINDTREE THERAPEUTICS INC /DE/

WINT financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 946486 Exchange: OTC SIC: 2836 (Biological Products, (No Diagnostic Substances)) Latest filing: 10-Q filed Nov 19, 2025 Data checked: Oct 21, 2026
Showing 3 of 15 annual and 0 of 61 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$1.90M (Jun 2024)
Industry (SIC)
2836 Biological Products, (No Diagnostic Substances)
Incorporated
DE
Fiscal Year End
December (1231)
Phone
2154889300
EIN
943171943
Headquarters
WARRINGTON, PA, 18976
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: DISCOVERY LABORATORIES INC /DE/ (1997–2016) · ANSAN PHARMACEUTICALS INC (1997–1997) · ANSAN INC (1996–1996)

▼ Key Metrics (TTM)

As of Sep 30, 2025
Financials
Revenue
-
Net Income
$-39.99M
Total Assets
$15.98M
Total Equity
$-11.61M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
344.5%
Return on Assets
-250.2%
Current Ratio
0.33x

▼ FY 2024 Summary Analysis

Annual report ending Dec 31, 2024

Overview and Growth

Fiscal 2024 results for WINDTREE THERAPEUTICS INC /DE/ included net loss of $1.79M. At period end, total assets were $27.88M, framing the scale of the company’s operating and financing commitments.

Profitability

The company recorded an operating loss of $26.14M after the reported operating expense base. The company ended the period with a net loss of $1.79M, extending the operating result through all remaining items. EBITDA was negative $26.05M, showing a deficit before interest, taxes, depreciation, and amortization. The pretax result was a loss of $1.79M, establishing the deficit before tax effects. The reported tax benefit was $6.00K, favorably bridging the pretax and after-tax results. The loss-to-equity relationship was 17.9%, placing the bottom-line deficit against shareholder capital. The net loss equaled 6.4% of period-end assets, showing the deficit relative to the asset base. The bottom-line deficit decreased from $20.29M in fiscal 2023 to $1.79M.

Liquidity and Capital Structure

Total assets were $27.88M, supported by $14.70M of liabilities and $10.00M of shareholder equity. At period end, current assets of $2.57M compared with current liabilities of $5.72M, defining the company’s short-term resource position. At 0.45x, current liabilities exceeded current assets and placed pressure on the company’s near-term liquidity position. The company held $1.78M in cash and equivalents, a narrower liquidity measure than total current assets. The cash balance equaled 31.1% of current liabilities, showing how much near-term coverage came from cash alone. Book equity represented 35.9% of total assets, quantifying the balance-sheet share supported by shareholder capital. The liabilities-to-assets relationship was 52.7%, placing reported obligations against the full positive asset balance. Measured against total assets, cash and equivalents represented 6.4%, a balance-sheet composition measure rather than a liquidity forecast. Compared with $32.41M in fiscal 2023, the current asset base moved 14.0% and finished lower. Against $3.39M of equity in fiscal 2023, the current book-equity balance moved 194.8% and ended higher. The reported cash balance changed 58.8% from $4.32M in fiscal 2023, ending lower year over year.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $15.40M, rather than cash generation from operations. Capital expenditures used $12.00K in addition to the operating cash outflow, increasing the total cash consumed by operations and investment during the period. The company recorded a $15.41M cash deficit after capital spending for the period. The cash deficit after capital spending represented 55.3% of the period-end asset base. The operating cash outflow widened to $15.40M from $13.44M in fiscal 2023.
Based on the annual report for the fiscal year ending Dec 31, 2024. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for WINDTREE THERAPEUTICS INC /DE/
Metric FY2024 📄 FY2023 📄 FY2022 📄
Income Statement
REVENUE
OPERATING EXPENSES
R&D Expense $16.28M $8.34M $11.10M
SG&A Expense $8.74M $9.20M $10.79M
Operating Income $-26.14M $-20.60M $-41.33M
NON-OPERATING INCOME / EXPENSE
Interest Expense - $50.00K $53.00K
Interest Income $70.00K $325.00K $109.00K
Other Income/Expense $-408.00K $31.00K $702.00K
Pretax Income $-1.79M $-20.29M $-40.58M
Income Tax $-6.00K $0 $-1.37M
Net Income $-1.79M $-20.29M $-39.21M
PER SHARE & SUPPLEMENTAL
EBITDA $-26.06M $-20.52M $-40.80M
Depreciation & Amortization $84.00K $82.00K $533.00K
Balance Sheet
ASSETS
Cash & Equivalents $1.78M $4.32M $6.17M
Other Current Assets $795.00K $1.06M $1.21M
Current Assets $2.57M $5.38M $7.38M
PP&E (Net) $111.00K $183.00K $262.00K
Goodwill - $0 $3.06M
Intangible Assets - - $9.70M
Other Noncurrent Assets (derived) - - $17.56M
Noncurrent Assets $25.30M $27.03M $30.58M
Total Assets $27.88M $32.41M $37.95M
LIABILITIES
Accounts Payable $1.88M $809.00K $249.00K
Other Current Liabilities $359.00K $900.00K $0
Current Liabilities $5.72M $4.00M $2.46M
Other Noncurrent Liabilities $3.80M $3.80M $3.80M
Noncurrent Liabilities $8.98M $25.02M $25.49M
Total Liabilities $14.70M $29.02M $27.94M
EQUITY
Common Stock $0 $0 $0
Additional Paid-in Capital $859.66M $851.27M $837.60M
Retained Earnings $-846.61M $-844.82M $-824.53M
Total Equity $10.00M $3.39M $10.01M
Temporary Equity $3.18M $0 -
Total Liabilities & Equity $27.88M $32.41M $37.95M
SUPPLEMENTAL
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-15.40M $-13.44M $-19.45M
Capital Expenditures $12.00K $15.00K $13.00K
Cash from Investing $-12.00K $-15.00K $197.00K
Cash from Financing $12.73M $11.60M $3.08M
Free Cash Flow $-15.41M $-13.45M $-19.47M
Beginning Cash (CFS) $4.47M $6.33M $22.50M
Net Change in Cash $-2.68M $-1.86M $-16.18M
Effect of FX on Cash $0 $0 $0
Calculated Ending Cash $1.79M $4.47M $6.33M
Cash per BS $1.78M $4.32M $6.17M
Cash scope difference (CFS − BS) $9.00K $150.00K $154.00K
Cash per CFS $1.79M $4.47M $6.33M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

Is WINDTREE THERAPEUTICS INC /DE/ profitable?

No. WINDTREE THERAPEUTICS INC /DE/ reported $-39.99M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.